[.
]
Action/Kinetics:
Acts as a mitotic inhibitor at the G
2 portion of the cell cycle to inhibit DNA synthesis. At high doses, cells entering mitosis are lysed, whereas at low doses, cells will not enter prophase.
t
1/2: biphasic, initial, 1.5 hr; final, 4-11 hr.
Effective plasma levels: 0.3-10 mcg/mL. Poor CNS penetration. Eliminated through both the urine and bile unchanged and as liver metabolites. Is water soluble.
Uses:
With combination therapy to treat refractory testicular tumors and small cell lung cancer.
Investigational: Alone or in combination to treat acute monocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, AIDS-associated Kaposi's sarcoma, Ewing's sarcoma. Also, choriocarcinoma; hepatocellular carcinoma; nonsmall cell lung, breast, endometrial, and gastric cancers; acute lymphocytic leukemia; soft tissue carcinoma; rhabdomyosarcoma.
Contraindications:
Lactation.
Special Concerns:
Safety and efficacy in children have not been established. Severe myelosuppression may occur.
Additional Side Effects:
Anaphylactic-type reactions hypotension, peripheral neuropathy, somnolence.
How Supplied:
Capsule: 50 mg;
Injection: 20 mg/mL;
Powder for Injection: 100 mg
Dosage
?IV
Testicular carcinoma.
50-100 mg/m
2/day on days 1-5 or 100 mg/m
2/day on days 1, 3, and 5 q 3-4 weeks (i.e., after recovery from toxic effects). Used in combination with other agents.
Small cell lung carcinoma.
35 mg/m
2/day for 4 days to 50 mg/m
2/day for 5 days, repeated q 3-4 weeks.
?Capsules
Small cell lung carcinoma.
70 mg/m
2 (rounded to the nearest 50 mg) daily for 4 days to 100 mg/m
2 (rounded to the nearest 50 mg) daily for 5 days; repeat q 3-4 weeks.
NOTE: Etopophos is given in higher concentrations than VePesid. Doses above are for VePesid.
